How Is Charles River Laboratories' Stock Performance Compared to Other Health Care Stocks?

Valued at a market cap of almost $7.7 billion, Charles River Laboratories International, Inc. (CRL) is a full service, early-stage contract research organization that provides drug discovery, non-clinical development, and safety testing services. Based in Wilmington, Massachusetts, the company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions accelerate their research and drug development efforts.

Companies worth $2 billion or more are typically classified as “mid-cap stocks,” and CRL fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the diagnostics & research industry. The company’s strength lies in its comprehensive service offering, providing end-to-end solutions across the entire drug development lifecycle, from discovery through preclinical and clinical stages. The company is particularly renowned for its expertise in preclinical services, including toxicology testing, pharmacology, and early-stage discovery.